Aurobindo Pharma Ltd.
NSE: AUROPHARMA · Healthcare
Sector
Healthcare
Size band
Mid cap
Market cap
77,223cr
P/E
36.2
ROE
8.7%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Glenmark Pharmaceuticals Ltd. | 20.0% | 23.1% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Aurobindo Pharma Ltd..
On air
20 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| CNBC AwaazCNBC Awaax · no registration attached | 2 Sep | +2.6% | -0.2% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 2 Sep | +2.0% | -0.1% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 2 Sep | +21.8% | -13.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 1 Sep | +21.8% | -13.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 1 Sep | +10.7% | — | still open |
| NDTV ProfitNDTV Profit · no registration attached | 1 Sep | +3.0% | -4.5% | still open |
| Zee BusinessZee Business · no registration attached | 25 Aug | +1.7% | -1.0% | still open |
| Zee BusinessZee Business · no registration attached | 25 Aug | +2.7% | -1.0% | still open |
| Zee BusinessZee Business · no registration attached | 10 Aug | +1.4% | — | still open |
| Zee BusinessZee Business · no registration attached | 10 Aug | +2.3% | — | still open |
| Zee BusinessZee Business · no registration attached | 10 Aug | +2.3% | -1.3% | still open |
| Zee BusinessZee Business · no registration attached | 10 Aug | +4.0% | -1.4% | still open |
| Zee BusinessZee Business · no registration attached | 10 Aug | +2.2% | -1.4% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 10 Aug | +2.5% | -1.1% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 10 Aug | +1.3% | -1.1% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Aug | +5.5% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Aug | +8.6% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Aug | +14.6% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Aug | +5.5% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Aug | +8.6% | — | still open |
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 51.9 | 51.8 | 51.8 | 51.8 | +0.1 |
| Foreign institutions | 16.4 | 15.2 | 13.9 | 14.2 | +2.2 |
| Domestic institutions | 25.1 | 25.9 | 27.7 | 27.6 | −2.5 |
| Retail & others | 6.6 | 7.1 | 6.6 | 6.4 | +0.2 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 425- Submission of notice published in newspapers.3 Sept 2026
- Copy of Newspaper Publication3 Sept 2026
- Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited'' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.1 Sept 2026
- Acquisition1 Sept 2026
- Press Release31 Aug 2026
- General Updates28 Aug 2026
- Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.28 Aug 2026
- Shareholders meeting28 Aug 2026
- Submission of Voting Results and Scrutinizer''s Report of 39th AGM of the Company held on August 27, 2026.28 Aug 2026
- Shareholders meeting27 Aug 2026
- Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.27 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates25 Aug 2026
- Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong25 Aug 2026
- Intimation of Investor/ Analyst meet scheduled on September 1, 2026.25 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates25 Aug 2026
- Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.24 Aug 2026
- General Updates24 Aug 2026
- General Updates21 Aug 2026
- General Updates17 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates14 Aug 2026
- General Updates14 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates13 Aug 2026
- Acquisition13 Aug 2026
- Copy of Newspaper Publication7 Aug 2026
- Copy of Newspaper Publication7 Aug 2026
The 25 most recent of 425 filings we hold for AUROPHARMA, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.